Conversion of oral alfacalcidol to oral calcitriol in the treatment of secondary hyperparathyroidism in chronic hemodialysis patients
Sandrine Rauscher(Hôpital Maisonneuve-Rosemont), Michel Vallée, Caroline Lamarche(University of British Columbia), Denis Ouimet(Hôpital Maisonneuve-Rosemont), Laurence Lepage(Hôpital Maisonneuve-Rosemont), Sarah Bezzaoucha(Hôpital Maisonneuve-Rosemont), Vincent Pichette(Hôpital Maisonneuve-Rosemont), Jean‐Philippe Lafrance(Université de Montréal), Georges Ouellet(Hôpital Maisonneuve-Rosemont), Martine Leblanc, Robert Bell(Hôpital Maisonneuve-Rosemont), Katherine Desforges(Hôpital Maisonneuve-Rosemont)
Cited by 10
Related Papers
Non-cystic Fibrosis Bronchiectasis
|Unknown|2012|254
Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial
|The Lancet|2022|236
Plasma Gelsolin and Its Association with Mortality and Hospitalization in Chronic Hemodialysis Patients
|Blood Purification|2017|164
Hemoperfusion for the Treatment of Poisoning: Technology, Determinants of Poison Clearance, and Application in Clinical Practice
|Seminars in Dialysis|2014|111
Guidelines for Diagnosis and Management of Infective Endocarditis in Adults
|JAMA Network Open|2023|108